Page 2 - Implicit Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The video has been deceptively edited.

Brisbane biotech company trials drug on US COVID-19 patients in bid to find 'new way to prevent people dying' of virus ThuThursday 15 updated 33 Professor Ian Frazer has developed an anti-inflammatory drug used to treat COVID-19 patients. ( Print text only Cancel A Brisbane biotech company, led by award-winning immunologist Ian Frazer, has created an anti-inflammatory drug, which is being trialled as a potential treatment for severely-ill COVID-19 patients in the United States. Key points: The drug is being trailed on 300 people in the US, with results expected in about six months If success...

2021-04-16 11:35:50 GMT2021-04-16 19:35:50(Beijing Time) Xinhua English SYDNEY, April 16 (Xinhua) -- A Brisbane and Seattle-based company said on Friday that a new therapeutic candidate for the treatment of COVID-19 patients will enter a clinical trial in the United States, led by Professor Ian Frazer, a former recipient of the Australian of the Year award. Developed by biotechnology company Implicit Bioscience, the drug IC14 will be tested in more than 400 COVID-19 patients in 10 to 15 hospitals across the United States this week. Volunteer participants will be assigned at random to r...

Health by Janelle Miles Premium Content   A Brisbane company's experimental anti-inflammatory drug is being tested as a potential treatment in COVID-19 patients as part of trials sponsored by the US Government. The drug, IC14, is being administered to Americans admitted to hospital with COVID-19 as part of two separate studies - in people on ventilators admitted to intensive care units and in others before they are ill enough for the ICU. IC14 was invented in the US but developed over more than a decade by Brisbane company Implicit Bioscience after its ...

Clinical trial of monoclonal antibody for treating respiratory disease in COVID-19 patients begins A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The laboratory-created monoclonal a...